Trial Profile
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cetuximab; Cisplatin; Ropidoxuridine
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 15 Mar 2023 Results (n=39) assessing the safety of nivolumab concomitant with 70 Gy intensity modulated radiation therapy and weekly cisplatin (arm 1), every 3-week cisplatin (arm 2), cetuximab (arm 3), or alone for platinum-ineligible patients (arm 4) in newly diagnosed intermediate- or high-risk locoregionally advanced head and neck squamous cell carcinoma, published in the International Journal of Radiation Oncology, Biology, Physics.
- 22 Nov 2022 Status changed from active, no longer recruiting to completed.
- 05 Jun 2019 Planned End Date changed from 1 Mar 2021 to 1 Dec 2023.